KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Preferred Shares (2017 - 2021)

Historic Preferred Shares for Arbutus Biopharma (ABUS) over the last 5 years, with Q3 2021 value amounting to $161.0 million.

  • Arbutus Biopharma's Preferred Shares rose 1004.07% to $161.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $161.0 million, marking a year-over-year increase of 1004.07%. This contributed to the annual value of $149.4 million for FY2020, which is 883.05% up from last year.
  • Arbutus Biopharma's Preferred Shares amounted to $161.0 million in Q3 2021, which was up 1004.07% from $155.9 million recorded in Q2 2021.
  • In the past 5 years, Arbutus Biopharma's Preferred Shares registered a high of $161.0 million during Q3 2021, and its lowest value of $49.8 million during Q4 2017.
  • For the 5-year period, Arbutus Biopharma's Preferred Shares averaged around $132.5 million, with its median value being $135.8 million (2019).
  • Its Preferred Shares has fluctuated over the past 5 years, first surged by 15338.69% in 2018, then surged by 880.99% in 2021.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Preferred Shares stood at $49.8 million in 2017, then skyrocketed by 153.39% to $126.1 million in 2018, then rose by 8.84% to $137.3 million in 2019, then grew by 8.83% to $149.4 million in 2020, then grew by 7.74% to $161.0 million in 2021.
  • Its Preferred Shares stands at $161.0 million for Q3 2021, versus $155.9 million for Q2 2021 and $152.6 million for Q1 2021.